Oncology - AbbVie Pro Germany:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • Prescribing Information can be found at the bottom of this page.

      Haematology

      VENCLYXTO®▼ (venetoclax)

      Select one of the indications below to find out more:

      Acute Myeloid Leukaemia (AML)
      Chronic Lymphocytic Leukaemia (CLL)

      Reference: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.

      May 2024

      VENCLYXTO (venetoclax) PRESCRIBING INFORMATION/SmPC
      img
      img
      This website is intended for Healthcare Professionals only. 

      If you are a patient, please refer to your doctor for any questions you may have regarding your health care.

      This site contains therapy area and product-specific information, some of which is promotional in nature.

      Our therapy areas
      Dermatology
      Gastroenterology
      Rheumatology
      Haematology
      Pharmacy
      Urology
      Neurology
      Virology
      Endocrinology
      Additional info
      Contact Us
      Terms of use
      Privacy Policy
      AbbVie Australia

      For Medical Information Enquiries regarding an AbbVie product please email medinfoanz@abbvie.com or call 1800 043 460.
      For an Adverse Event in relation to the use of an AbbVie product please contact Pharmacovigilance via email anzpv@abbvie.com or call 1800 043 460.

      AbbVie Pty Ltd. Gateway 241, Level 7, 241 O'Riordan Street. MASCOT, NSW 2020
      Copyright © 2022. AbbVie is a member of Medicines Australia.  | AU-ABBV-200027. June 2023